Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clemens-Martin Wendtner

Showing results (21-30 of 106) with videos related to

Pageof 11
Sort By:
Blood|October 9, 2004
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytesChristine Mayr, Dagmar Bund, Martin Schlee, et al.
Blood|June 14, 2008
The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genesAditya Veldurthy, Michaela Patz, Susanne Hagist, et al.
Experimental Hematology|January 18, 2006
MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytesChristine Mayr, Dagmar Bund, Martin Schlee, et al.
Infection|April 11, 2025
Burden of COVID-19 in immunocompromised patients in Germany: a retrospective, observational Study on Health Insurance Data from 2021 to 2022Julia Weinmann-Menke, Clemens-Martin Wendtner, Dennis Häckl, et al.
British Journal of Haematology|November 20, 2008
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)Carmen D Schweighofer, Matthias Ritgen, Barbara F Eichhorst, et al.
Blood|September 24, 2005
Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemiaChristine Mayr, Michael R Speicher, David M Kofler, et al.
Onkologie|August 1, 2012
Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cellsMirjam Kuckertz, Michaela Patz, Aditya Veldurthy, et al.
European Journal of Haematology|January 6, 2025
SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron EraManuela A Hoechstetter, Eva-Maria Hollwich, Doris Illner, et al.
British Journal of Haematology|November 25, 2010
Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosisLukas P Frenzel, Michaela Patz, Christian P Pallasch, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 18, 2011
CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activationDavid M Kofler, Markus Chmielewski, Gunter Rappl, et al.
Pageof 11

Showing results (21-30 of 106) with videos related to

Sort By:
Pageof 11
Blood|October 9, 2004
Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytesChristine Mayr, Dagmar Bund, Martin Schlee, et al.
Blood|June 14, 2008
The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genesAditya Veldurthy, Michaela Patz, Susanne Hagist, et al.
Experimental Hematology|January 18, 2006
MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytesChristine Mayr, Dagmar Bund, Martin Schlee, et al.
Infection|April 11, 2025
Burden of COVID-19 in immunocompromised patients in Germany: a retrospective, observational Study on Health Insurance Data from 2021 to 2022Julia Weinmann-Menke, Clemens-Martin Wendtner, Dennis Häckl, et al.
British Journal of Haematology|November 20, 2008
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)Carmen D Schweighofer, Matthias Ritgen, Barbara F Eichhorst, et al.
Blood|September 24, 2005
Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemiaChristine Mayr, Michael R Speicher, David M Kofler, et al.
Onkologie|August 1, 2012
Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cellsMirjam Kuckertz, Michaela Patz, Aditya Veldurthy, et al.
European Journal of Haematology|January 6, 2025
SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron EraManuela A Hoechstetter, Eva-Maria Hollwich, Doris Illner, et al.
British Journal of Haematology|November 25, 2010
Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosisLukas P Frenzel, Michaela Patz, Christian P Pallasch, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 18, 2011
CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activationDavid M Kofler, Markus Chmielewski, Gunter Rappl, et al.
Pageof 11